Tanzania’s New Health Policy To Recognise Neglected Tropical Diseases 11/12/2018 Kizito Makoye TABORA, Tanzania -- At first glance, the village looks quiet and beautiful. Unfortunately, life has not been affirming for dozens of its inhabitants. They have leprosy—a least contagious and curable disease, except for its two worst characteristics — poverty and neglect. Continue reading -> WHO Emergencies Head Praises Collaboration With Pharma On Ebola, Calls For Expanded “Strategic” Collaboration 05/12/2018 Health Policy Watch The current Ebola outbreak in the Democratic Republic of Congo (DRC) is the second largest ever, occurring in a “perfect storm” of a densely-populated conflict zone. Yet thanks in large part to a strong collaboration between the World Health Organization and the pharmaceutical industry, the outbreak has so far remained confined to two DRC provinces, says Peter Salama, WHO deputy director general for emergency preparedness and response. Continue reading -> First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> WHO Declaration Of Astana: New Global Commitment To Strengthen Primary Health Care 25/10/2018 David Branigan Countries around the world today agreed to the Declaration of Astana, “vowing to strengthen their primary health care systems as an essential step toward achieving universal health coverage,” according to a World Health Organization press release. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Emergencies Head Praises Collaboration With Pharma On Ebola, Calls For Expanded “Strategic” Collaboration 05/12/2018 Health Policy Watch The current Ebola outbreak in the Democratic Republic of Congo (DRC) is the second largest ever, occurring in a “perfect storm” of a densely-populated conflict zone. Yet thanks in large part to a strong collaboration between the World Health Organization and the pharmaceutical industry, the outbreak has so far remained confined to two DRC provinces, says Peter Salama, WHO deputy director general for emergency preparedness and response. Continue reading -> First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> WHO Declaration Of Astana: New Global Commitment To Strengthen Primary Health Care 25/10/2018 David Branigan Countries around the world today agreed to the Declaration of Astana, “vowing to strengthen their primary health care systems as an essential step toward achieving universal health coverage,” according to a World Health Organization press release. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
First WHO Global Coordination Meeting On NCDs Sets Actions For Future 07/11/2018 Catherine Saez According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading -> WHO Declaration Of Astana: New Global Commitment To Strengthen Primary Health Care 25/10/2018 David Branigan Countries around the world today agreed to the Declaration of Astana, “vowing to strengthen their primary health care systems as an essential step toward achieving universal health coverage,” according to a World Health Organization press release. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Declaration Of Astana: New Global Commitment To Strengthen Primary Health Care 25/10/2018 David Branigan Countries around the world today agreed to the Declaration of Astana, “vowing to strengthen their primary health care systems as an essential step toward achieving universal health coverage,” according to a World Health Organization press release. Continue reading -> Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Tobacco Convention Chief Hails Advances But Offers Warnings And Flags Concerns Tobacco Industry Continues “Furious Efforts” To Undermine Treaty 02/10/2018 John Zarocostas The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading -> Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Posts navigation Older postsNewer posts